NYSE · Biotechnology

Arcus Biosciences, Inc. (RCUS) Stock

$24.41 +2.43% NYSE: RCUS Healthcare

Valuation

MetricValue
Price$24.41
Market Cap$3.07B
P/E Ratio-6.22
P/B Ratio6.64
P/S Ratio26.27
EPS (TTM)$-3.29
52-Week High$31.74
52-Week Low$13.61
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-87.98%
ROA-48.92%
ROCE-66.94%
Gross Margin-156.28%
Operating Margin-156.28%
Net Margin-386.32%
Debt/Equity0.25
Current Ratio4.36

Annual Financials (USD)

Metric20212022202320242025
Revenue$383.0M$112.0M$117.0M$258.0M$247.0M
Operating Profit$54.0M$-280.0M$-340.0M$-330.0M$-386.0M
Net Profit$53.0M$-267.0M$-307.0M$-283.0M$-353.0M
EPS$0.71$-3.71$-4.15$-3.14$-3.29
Op Margin14.1%-250.0%-290.6%-127.9%-156.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.6B$1.3B$1.1B$1.1B$1.1B
Total Liabilities$750.0M$688.0M$633.0M$665.0M$508.0M
Cash$148.0M$206.0M$127.0M$150.0M$222.0M
Borrowings$122.0M$120.0M$11.0M$60.0M$112.0M

Latest News

Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients Business Wire · Jul 22, 2026 Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer Business Wire · Jul 22, 2026 RCUS: Raising target price to $31.00 Argus Research · Jul 22, 2026 Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates Business Wire · Jul 21, 2026 An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% Run Motley Fool · Jul 13, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-256.0M$438.0M$-306.0M$-170.0M$-482.0M
Investing Cash Flow$-30.0M$-419.0M$170.0M$-90.0M$64.0M
Financing Cash Flow$0$10.0M$8.0M$2.0M$0
Net Cash Flow$-26.0M$58.0M$-79.0M$23.0M$72.0M
Free Cash Flow$-282.0M$432.0M$-330.0M$-176.0M$-484.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.30
EV / EBITDA-7.25
FCF Yield-15.45%
Quick Ratio3.82
Interest Coverage-21.13
Return 1Y190.25%
Return 3Y40.85%
Return 5Y3.83%

Ownership

Insiders Held29.15%
Institutions Held72.62%
Institutions Float Held102.50%
Institutional HolderSharesReport Date
Gilead Sciences Inc31,424,7602026-03-31
Blackrock Inc.15,226,4752026-03-31
Wellington Management Group, LLP6,089,5162026-03-31
State Street Corporation5,412,9012026-03-31
Suvretta Capital Management, LLC5,030,9932026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AGIOAgios Pharmaceuticals, Inc. $31.81 -0.34% -4.54 $1.90B 0.00%
BEAMBeam Therapeutics Inc. $25.70 +4.47% -29.88 $2.64B 0.00%
COGTCogent Biosciences, Inc. $31.00 +3.06% -13.36 $5.30B 0.00%
DNLIDenali Therapeutics Inc. $19.45 +4.18% -7.04 $3.09B 0.00%
ETNB89bio, Inc. $14.84 +0.00% -12.82 $2.20B 0.00%

About Arcus Biosciences, Inc.

Arcus Biosciences, Inc. (RCUS) stock trades at $24.41 with a market capitalization of $3.07B. The stock is valued at a price-to-earnings (P/E) ratio of -6.22, price-to-book of 6.64, price-to-sales of 26.27. Over the past 52 weeks the stock has ranged between $13.61 and $31.74, and currently trades 23.1% below its 52-week high.

On profitability, Arcus Biosciences, Inc. generates a return on equity (ROE) of -87.98%, return on capital employed of -66.94%, an operating margin of -156.28%, a net profit margin of -386.32%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNYSE High ROE StocksAll stock screens
Run Stock Screener Investing Guides